SCHEMBL6784147

SCHEMBL6784147

COC(=O)c1cc(Br)ccc1NC(=O)/C=C(/C)c1ccc2ccccc2c1

nearest known ligand 0.64

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
TERT O14746 5/20 0.64
ALDH1A1 P00352 4/20 0.52
GAA P10253 1/20 0.52
DHODH Q02127 2/20 0.49
KDM4E B2RXH2 4/20 0.47
ALOX12 P18054 1/20 0.47
MEN1 O00255 3/20 0.44
KMT2A Q03164 3/20 0.44
ABCG2 Q9UNQ0 1/20 0.44
LTB4R Q15722 1/20 0.42
MAPT P10636 2/20 0.41
LMNA P02545 1/20 0.41
PLAU P00749 1/20 0.41
RAB9A P51151 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
SLC6A2 P23975 1/20 0.40
SLC6A4 P31645 1/20 0.40
SLC6A3 Q01959 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4021470 0.89 TERT (0.77) TERTDHODHKDM4EMEN1KMT2A
SCHEMBL4024547 0.89 TERT (0.77) TERTDHODHKDM4EMEN1KMT2A
SCHEMBL4024549 0.89 TERT (0.77) TERTDHODHKDM4EMEN1KMT2A
SCHEMBL6782055 0.88 TERT (0.65) TERTALDH1A1KDM4EALOX12MEN1
SCHEMBL6784219 0.88 TERT (0.78) TERTALDH1A1GAAKDM4EALOX12
SCHEMBL6784696 0.88 TERT (0.67) TERTALDH1A1GAAKDM4EALOX12
SCHEMBL6783555 0.87 TERT (0.64) TERTALDH1A1KDM4EALOX12MEN1
SCHEMBL6781638 0.83 TERT (0.61) TERTALDH1A1GAAKDM4EKMT2A
SCHEMBL6787247 0.83 TERT (0.59) TERTALDH1A1GAAKDM4EALOX12
SCHEMBL6782397 0.83 TERT (0.64) TERTALDH1A1GAAKDM4EALOX12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6727250-B2 ADMINISTERING COMPOUNDS SUCH AS TRANS-3-(NAPHTH-2-YL)-BUT-2-ENOIC ACID-N-(2-CARBOXY-PHENYL)-AMIDE OR LIKE FOR THERAPY OF CONDITIONS ASSOCIATED WITH INCREASED TELOMERASE ACTIVITY, E.G. TUMOUR DISEASES BOEHRINGER INGELHEIM PHARMA KG (DE) 2004-04-27 US disclosed
EP-1261321-A2 CARBOXYLIC ACID AMIDES, MEDICAMENTS CONTAINING THESE COMPOUNDS AND THE USE AND PRODUCTION THEREOF Boehringer Ingelheim Pharma KG (DE) 2002-12-04 EP disclosed
US-20020099089-A1 Carboxylic acid amides, pharmaceutical compositions containing these compounds, their use and preparation BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2002-07-25 US disclosed
US-6362210-B1 ANTITUMOR, ANTICANCER AGENT BOEHRINGER INGELHEIM PHARMA KG (DE) 2002-03-26 US disclosed
WO-2001007020-A2 CARBOXYLIC ACID AMIDES, MEDICAMENTS CONTAINING THESE COMPOUNDS AND THE USE AND PRODUCTION THEREOF BOEHRINGER INGELHEIM PHARMA KG (DE) 2001-02-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020099089-A1 Carboxylic acid amides, pharmaceutical compositions containing these compounds, their use and preparation TERT, NAT1, POT1 TERT 1/4885ALDH1A1 102/4885GAA 262/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.